Determination of soluble vascular endothelial growth factor receptor 3 (sVEGFR-3) in plasma as pharmacodynamic biomarker

Journal of Pharmaceutical and Biomedical Analysis

Volumn 70, Issue , 2012, Pages 485-491

  Kanefendt, Friederike ^a   Lindauer, Andreas ^a   Mross, Klaus ^b   Fuhr, Uwe ^c   Jaehde, Ulrich ^a  

^a UNIVERSITY OF BONN   (Germany)

^b TUMOR BIOLOGY CENTER   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Angiogenesis; Biomarker; Immunoassay; Sunitinib; SVEGFR 3

Indexed keywords

SOLUBLE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 3; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 3;

ACCURACY; ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; METASTASIS; METASTATIC COLORECTAL CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ANGIOGENESIS INHIBITORS; CALIBRATION; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GERMANY; HUMANS; INDOLES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PROTEIN STABILITY; PYRROLES; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84866256300     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.06.039     Document Type: Article

References (30)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 1990, 82:4-6.
2. Chau C.H., Rixe O., McLeod H., Figg W.D. Validation of analytic methods for biomarkers used in drug development. Clin. Cancer Res. 2008, 14:5967-5976.
3. Jubb A.M., Oates A.J., Holden S., Koeppen H. Predicting benefit from anti-angiogenic agents in malignancy. Nat. Rev. Cancer 2006, 6:626-635.
4. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69:89-95. Biomarker Definition Working Group.
5. Cummings J., Ward T.H., Greystoke A., Ranson M., Dive C. Biomarker method validation in anticancer drug development. Br. J. Pharmacol. 2008, 153:646-656.
6. Faivre S., Demetri G., Sargent W., Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov. 2007, 6:734-745.
7. Burstein H.J., Elias A.D., Rugo H.S., Cobleigh M.A., Wolff A.C., Eisenberg P.D., Lehman M., Adams B.J., Bello C.L., Deprimo S.E., Baum C.M., Miller K.D. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 2008, 26:1810-1816.
8. DePrimo S.E., Bello C. Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib. Ann. Oncol. 2007, 18(Suppl. 10):x11-x19.
9. DePrimo S.E., Bello C., Smeraglia J., Baum C., Spinella D., Rini B., Michaelson M.D., Motzer R. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J. Transl. Med. 2007, 5:32-42.
10. Kontovinis L.F., Papazisis K.T., Touplikioti P., Andreadis C., Mouratidou D., Kortsaris A.H. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer 2009, 9:82-91.
11. Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., Ginsberg M.S., Kim S.T., Baum C.M., Deprimo S.E., Li J.Z., Bello C.L., Theuer C.P., George D.J., Rini B.I. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006, 24:16-24.
12. Norden-Zfoni A., Desai J., Manola J., Beaudry P., Force J., Maki R., Folkman J., Bello C., Baum C., DePrimo S.E., Shalinsky D.R., Demetri G.D., Heymach J.V. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin. Cancer Res. 2007, 13:2643-2650.
13. Rini B.I., Michaelson M.D., Rosenberg J.E., Bukowski R.M., Sosman J.A., Stadler W.M., Hutson T.E., Margolin K., Harmon C.S., Deprimo S.E., Kim S.T., Chen I., George D.J. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 2008, 26:3743-3748.
14. Harmon C.S., Deprimo S.E., Raymond E., Cheng A.L., Boucher E., Douillard J.Y., Lim H.Y., Kim J.S., Lechuga M.J., Lanzalone S., Lin X., Faivre S. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. J. Transl. Med. 2011, 9:120-133.
15. Saltz L.B., Rosen L.S., Marshall J.L., Belt R.J., Hurwitz H.I., Eckhardt S.G., Bergsland E.K., Haller D.G., Lockhart A.C., Rocha Lima C.M., Huang X., DePrimo S.E., Chow-Maneval E., Chao R.C., Lenz H.J. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J. Clin. Oncol. 2007, 25:4793-4799.
16. Achen M.G., Stacker S.A. Molecular control of lymphatic metastasis. Ann. N. Y. Acad. Sci. 2008, 1131:225-234.
17. Mouawad R., Spano J.P., Comperat E., Capron F., Khayat D. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. Eur. J. Cancer 2009, 45:1407-1414.
18. Findlay J.W., Smith W.C., Lee J.W., Nordblom G.D., Das I., DeSilva B.S., Khan M.N., Bowsher R.R. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J. Pharm. Biomed. Anal. 2000, 21:1249-1273.
19. European Medicines Agency, Guideline on Bioanalytical Method Validation, EMEA/CHMP/EWP/192217/2009, 2011.
20. FDA Guidance for Industry - Bioanalytical Method Validation 2001, US Department of Health and Human Services FDA (CDER) and (CVM).
21. DeSilva B., Smith W., Weiner R., Kelley M., Smolec J., Lee B., Khan M., Tacey R., Hill H., Celniker A. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 2003, 20:1885-1900.
22. Lee J.W., Devanarayan V., Barrett Y.C., Weiner R., Allinson J., Fountain S., Keller S., Weinryb I., Green M., Duan L., Rogers J.A., Millham R., O'Brien P.J., Sailstad J., Khan M., Ray C., Wagner J.A. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 2006, 23:312-328.
23. Valentin M.A., Ma S., Zhao A., Legay F., Avrameas A. Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies. J. Pharm. Biomed. Anal. 2011, 55:869-877.
24. Smolec J., DeSilva B., Smith W., Weiner R., Kelly M., Lee B., Khan M., Tacey R., Hill H., Celniker A., Shah V., Bowsher R., Mire-Sluis A., Findlay J.W., Saltarelli M., Quarmby V., Lansky D., Dillard R., Ullmann M., Keller S., Karnes H.T. Bioanalytical method validation for macromolecules in support of pharmacokinetic studies. Pharm. Res. 2005, 22:1425-1431.
25. Findlay J.W. Some important considerations for validation of ligand-binding assays. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2008, 877:2192-2197.
26. Findlay J.W., Dillard R.F. Appropriate calibration curve fitting in ligand binding assays. AAPS J. 2007, 9:E260-E267.
27. Hormbrey E., Gillespie P., Turner K., Han C., Roberts A., McGrouther D., Harris A.L. A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful?. Clin. Exp. Metastasis 2002, 19:651-663.
28. Lindauer A., Di Gion P., Kanefendt F., Tomalik-Scharte D., Kinzig M., Rodamer M., Dodos F., Sorgel F., Fuhr U., Jaehde U. Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers. Clin. Pharmacol. Ther. 2010, 87:601-608.
29. Kanefendt F., Lindauer A., Kinzig M., Strumberg D., Scheulen M.E., Mross K., Fischer R., Moritz B., Sörgel F., Jaehde U. Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients. Int. J. Clin. Pharmacol. Ther. 2011, 49:88-90.
30. Mross K., Buchert M., Fasol U., Jaehde U., Kanefendt F., Strumberg D., Arends J., Hense J., Moritz B., Fischer R., Scheulen M.E. A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment. Int. J. Clin. Pharmacol. Ther. 2011, 49:96-98.